Key takeaways
- Dividend income crosses the border: US dividend stocks give Canadian investors access to sectors and business models that simply don’t exist on the TSX, from specialty insurance to semiconductor manufacturing to biotech, and many of these companies are growing their payouts at a pace most Canadian dividend payers can’t match.
- Growth and income aren’t exclusive: The standout names on this list aren’t just paying dividends for the sake of it. They’re backed by real earnings momentum in areas like cloud networking, gold mining, and electric vehicle infrastructure, meaning you’re not sacrificing capital appreciation potential just to collect a quarterly cheque.
- Watch withholding taxes and volatility: Canadians buying US dividend stocks face a 15% withholding tax in registered accounts like TFSAs (RRSPs get a treaty exemption), which eats into your yield. On top of that, some of these sectors, particularly gold miners and smaller industrial names, can swing hard on commodity prices or shifting government policy, so position sizing matters more than usual.
Canadian investors love their dividends, and I get it. But if your entire income portfolio is Canadian bank stocks and pipelines, you’re leaving a lot on the table. The U.S. market is home to companies paying meaningful dividends across sectors that barely exist on the TSX, from specialty insurance to semiconductor manufacturing to biotech. That geographic diversification isn’t just nice to have. It’s a real risk reducer.
One thing I want to be upfront about: “dividend stock” means something different south of the border. Yields tend to be lower than what Canadians are used to, partly because U.S. companies are more aggressive with buybacks and partly because growth rates are often higher. A 1.5% yield that’s growing at 15% a year will outperform a 5% yield that’s stagnant. That math isn’t intuitive for a lot of people, but it’s the reason I lean toward dividend growth over raw yield almost every time.
The tax angle matters too. U.S. dividends don’t qualify for the Canadian dividend tax credit, so holding these names in an RRSP (where the 15% withholding tax is waived) makes a meaningful difference to your after-tax return. If you’re building out your RRSP, U.S. dividend payers are a natural fit.
This list is deliberately eclectic. I didn’t want ten mega-cap household names you’ve already heard of a thousand times. Some of these are large, established businesses. Others are mid-caps with strong cash flow profiles and dividend policies that are just getting started. The common thread is that every one of them generates real free cash flow, has a defensible market position, and pays a dividend that I believe is sustainable.
What mattered most to me was the quality of the underlying business. A dividend is only as good as the earnings behind it.
In This Article
- Bristol-Myers Squibb Company (BMY)
- AT&T Inc. (T)
- Progressive Corporation (PGR)
- Altria Group Inc. (MO)
- Comcast Corporation (CMCSA)
- Verizon Communications Inc (VZ)
- PepsiCo Inc. (PEP)
- Chevron Corporation (CVX)
- Medtronic plc (MDT)
- Duke Energy Corporation (DUK)
Bristol-Myers Squibb Company (NYSE: BMY)
$57.18
Overall Grade7.0 / 10
Bristol-Myers Squibb Company, established in its current form in 1989 following a merger, is a global biopharmaceutical firm operating within the healthcare sector. It focuses on developing and commercializing innovative medicines in areas such as oncology, immunology, and cardiovascular diseases...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E17.0
P/B6.2
P/S2.6
P/FCF10.4
FCF Yield+9.6%
Growth & Outlook
Rev Growth (YoY)+0.6%
EPS Growth (YoY)+2.9%
Revenue 5yr+0.9%
EPS 5yr+2.7%
FCF 5yr-10.2%
Fundamentals
Market Cap$123.8B
Dividend Yield4.4%
Operating Margin+20.5%
ROE+37.7%
Interest Coverage23.1x
Competitive Edge
- BMY's Growth Through Replenishment portfolio (Opdivo, Yervoy, Reblozyl, Camzyos, Sotyktu, Breyanzi) is diversified across oncology, hematology, cardiology, and immunology, reducing single-product dependency as Eliquis and Revlimid decline.
- CAR-T therapy Breyanzi and cardiac myosin inhibitor Camzyos address markets with limited competition and high switching costs once patients are stabilized. These are not commodity drugs vulnerable to generic erosion in the near term.
- BMY's deep oncology franchise creates a clinical trial ecosystem advantage. Oncologists running Opdivo combination trials generate data and relationships that make BMY a preferred partner for licensing and co-development deals.
- The Celgene acquisition, despite its balance sheet impact, gave BMY ownership of the Revlimid cash flow stream that funded the current pipeline buildout. That reinvestment cycle is now producing late-stage assets across multiple therapeutic areas.
- Regulatory expertise in biologics and cell therapy creates a meaningful barrier. CAR-T manufacturing and FDA approval pathways are complex enough that smaller competitors face years of delay replicating BMY's commercial-scale infrastructure.
By the Numbers
- Forward P/E of 9.1x vs trailing 16.2x implies consensus expects EPS to nearly double from $3.46 to $6.32, and the PEG of 0.12 suggests the market is dramatically underpricing that earnings inflection relative to growth.
- FCF margin of 24.6% vastly exceeds net margin of 15.0%, with FCF-to-net-income conversion at 1.64x. This signals high earnings quality, as non-cash charges (likely amortization of acquired intangibles) depress GAAP income well below actual cash generation.
- FCF yield of 10.1% combined with a 4.1% dividend yield and 4.8% debt paydown yield produces a total shareholder yield of 4.3%. The FCF payout ratio at 42.7% leaves substantial headroom to simultaneously service debt and sustain the dividend.
- SBC at just 1.1% of revenue ($555M) is minimal for a $48B revenue company. Share count grew only 0.1% YoY, meaning dilution is negligible and buybacks nearly offset compensation grants.
- Interest coverage at 31.4x is exceptionally strong relative to 2.2x debt-to-equity, indicating BMY locked in favorable rates on its $44.5B debt stack before the rate cycle turned. Refinancing risk is low near-term.
Risk Factors
- Consensus estimates project revenue declining from $47.3B (Y1) to $36.6B (Y5), a 23% cumulative drop. This is the Revlimid/Eliquis patent cliff in plain numbers, and no amount of margin management can fully offset that top-line erosion.
- FCF has contracted at a -10.2% 5Y CAGR and -16.5% 3Y CAGR, with the most recent year down 30.3% YoY. The growth grade of 3.7/10 confirms this trajectory. Cash generation is deteriorating even as the income statement holds steady.
- Tangible book value per share is negative at -$9.76, driven by intangibles at 46.2% of assets and goodwill at 25.1%. This $71B+ in intangible assets from the Celgene and other acquisitions carries meaningful impairment risk as legacy products lose exclusivity.
- R&D spend at 28.8% of revenue is high even for pharma, yet 5Y revenue CAGR is under 1%. The pipeline must replace roughly $10B+ in revenue losses over the next five years just to stay flat, and the R&D investment has not yet produced visible top-line results.
- The 69.7% earnings payout ratio looks stretched against declining EPS estimates (from $6.32 Y1 to $4.85 Y5). If EPS tracks toward $4.85, the $2.49 dividend would consume over 51% of earnings, but the real risk is whether FCF holds up as revenue contracts.
AT&T Inc. (NYSE: T)
$24.80
Overall Grade6.8 / 10
AT&T Inc. is a diversified telecommunications company operating in wireless, broadband, video, and entertainment services...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E9.7
P/B1.8
P/S1.6
P/FCF33.5
FCF Yield+3.0%
Growth & Outlook
Rev Growth (YoY)+0.7%
EPS Growth (YoY)-2.0%
Revenue 5yr-1.1%
EPS 5yr+1.8%
FCF 5yr-2.3%
Fundamentals
Market Cap$201.9B
Dividend Yield4.5%
Operating Margin+19.8%
ROE+3.3%
Interest Coverage-3.6x
Competitive Edge
- AT&T's fiber buildout creates a structural moat in passed locations. Once fiber is deployed, the economics of overbuilding are prohibitive for competitors. The 30M+ fiber passings target gives AT&T a locked-in addressable market with 35%+ penetration rates and rising ARPU.
- The wireless duopoly with Verizon in postpaid creates pricing discipline that cable MVNOs and T-Mobile cannot fully disrupt. AT&T's FirstNet contract with the federal government provides a captive, high-value subscriber base with minimal churn and long-term revenue visibility.
- The WarnerMedia divestiture removed content risk and execution complexity, allowing management to focus capital on network infrastructure where returns are more predictable. This strategic simplification reduced the conglomerate discount that plagued the stock for years.
- Fixed wireless access (Internet Air) with 1.74M subscribers and 239K quarterly net adds creates a capital-light broadband alternative in areas where fiber economics don't work, extending the addressable market without proportional capex.
By the Numbers
- Trailing P/E of 8.5x against EV/EBITDA of 7.3x and an earnings yield of 11.8% signals the market is pricing AT&T like a declining business, yet consensus estimates project EPS growing from $2.31 to $3.53 over five years, a 9%+ CAGR. The Valuation grade of 10/10 reflects this disconnect.
- Fiber broadband connections grew from 5.99M in FY2021 to 10.4M in FY2025, a 74% increase, while fiber net adds actually reaccelerated to 1.075M in FY2025 after two years of deceleration. This is the highest-quality growth engine in the business and it is still gaining momentum.
- Consumer Wireline revenue growth accelerated every year from 1.7% in FY2022 to 4.5% in FY2025, driven by fiber mix shift. This segment is becoming a meaningful growth contributor, not just a legacy drag offset.
- OCF-to-net-income ratio of 6.5x is extremely high, indicating reported net income is heavily depressed by non-cash charges (depreciation, amortization, impairments) while actual cash generation remains strong. Unlevered FCF of $21.8B dwarfs the $4.2B net income figure.
- Latin America turned from a $510M operating loss in FY2021 to a $145M profit in FY2025, with operating contribution surging 262% YoY. This segment is now accretive after years of being a drag, removing a persistent headwind to consolidated margins.
Risk Factors
- FCF payout ratio of 134% means AT&T is paying more in dividends than it generates in free cash flow. With capex consuming 78% of operating cash flow and capex/depreciation at 1.04x, the dividend is effectively funded by the gap between OCF and FCF, leaving zero margin for error.
- Postpaid phone churn spiked to 0.90% in FY2025 from 0.76% in FY2024, an 18.4% YoY increase. Postpaid net adds fell 22.8% YoY to 1.74M while prepaid lost 536K subscribers. The wireless growth engine is clearly decelerating, and competitive intensity is rising.
- Tangible book value per share is negative $12.55, driven by intangibles comprising 47.3% of total assets and goodwill at 15.2%. This means the entire equity value rests on the earnings power of acquired assets, with meaningful impairment risk if EBITDA disappoints.
- Business Wireline revenue declined at an accelerating rate: -5.8%, -7.3%, -9.9%, -8.4% over FY2022-FY2025. This segment still generates $17.2B in revenue, so each percentage point of decline represents roughly $170M in lost high-margin legacy revenue that must be replaced.
- Interest coverage is reported at negative 6.6x, which alongside $157B in total debt and net debt/EBITDA of 3.0x, means refinancing risk is real. With $145B in net debt, every 50bps increase in blended borrowing cost adds roughly $725M in annual interest expense.
Progressive Corporation (NYSE: PGR)
$190.40
Overall Grade6.7 / 10
Progressive Corporation, founded in 1937, is a major U.S. insurance provider specializing in auto, home, and other property and casualty coverages...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E10.1
P/B3.6
P/S1.3
P/FCF6.8
FCF Yield+14.7%
Growth & Outlook
Rev Growth (YoY)+2.0%
EPS Growth (YoY)+2.3%
Revenue 5yr+13.4%
EPS 5yr+28.2%
FCF 5yr+21.9%
Fundamentals
Market Cap$115.8B
Dividend Yield7.3%
Operating Margin+16.6%
ROE+37.1%
Interest Coverage53.3x
Competitive Edge
- Progressive's direct-to-consumer channel and Snapshot telematics create a data feedback loop that competitors like Allstate and GEICO cannot easily replicate. More drivers means better pricing models, which means better loss ratios, which attracts more drivers.
- The bundling strategy through homeowners (via ASI/Homesite) creates switching cost stickiness. Auto-only customers churn at roughly 2x the rate of bundled customers, and Progressive's property segment is now integrated into the personal lines reporting.
- Progressive's agency and direct dual-distribution model gives it access to both price-sensitive shoppers and relationship-driven buyers. GEICO lacks the agency channel, and State Farm lacks the direct digital infrastructure at comparable scale.
- Monthly reporting of financial results (unique among major insurers) creates a transparency advantage that attracts institutional capital and reduces information asymmetry, effectively lowering the company's cost of equity versus peers.
- Regulatory moat in auto insurance is underappreciated. State-by-state rate filing requirements create a 6-18 month lag for competitors to match pricing actions, giving first-movers like Progressive a sustained advantage in rate adequacy cycles.
By the Numbers
- Combined ratio improved from 95.8 in FY2022 to 87.4 in the latest quarter, a 840bps improvement driven primarily by loss ratio compression from 77.3 to 65.9. This is elite underwriting discipline, not just rate adequacy.
- FCF-to-net-income conversion of 1.47x signals high earnings quality. For an insurer, this means reserve releases or favorable loss development are flowing through to cash, not just paper profits.
- Personal Lines net premiums written grew 23.5% in FY2024 and 14.3% in FY2025, compounding on a $38.4B base in FY2021 to $72.6B. Progressive is gaining share at an unprecedented rate while simultaneously improving profitability.
- ROE of 37.1% on a tangible book of $54.51 per share with zero goodwill or intangibles. This is pure operating return, not inflated by acquisition accounting. At 3.7x book, the market is pricing in sustained mid-30s ROE.
- SBC-to-revenue of just 0.14% ($124M on $87.7B revenue) is negligible. Unlike tech companies where SBC masks true costs, Progressive's reported earnings are essentially cash earnings with minimal dilution drag.
Risk Factors
- Forward P/E of 12.45x exceeds trailing P/E of 10.3x, meaning consensus expects EPS to decline from $19.23 to ~$16.38, a 15% drop. The market is pricing in combined ratio normalization, and analysts see FY2025-FY2027 EPS flat to declining.
- Underwriting expense ratio has risen from 17.3 in FY2023 to 21.5 in the latest period, a 24% increase. This offsets loss ratio gains and suggests growth-related spending (advertising, agent commissions) is accelerating faster than premium volume.
- Payout ratio of 70.5% on earnings versus 48.1% on FCF reveals the $13.90 dividend per share is consuming a large share of reported income. If combined ratios revert toward 95, the dividend could become constrained quickly.
- Commercial Lines net premiums written declined 3.1% in FY2025 after years of 8-17% growth. This deceleration, combined with quarterly QoQ volatility of -5.5% and -6.8%, suggests pricing competition or deliberate pullback in a segment that was a key growth driver.
- Revenue growth YoY slowed to just 2% despite 14%+ net premiums written growth, indicating earned premium recognition is lagging written premium growth. This timing gap will eventually close, but near-term reported revenue understates the business trajectory.
Altria Group Inc. (NYSE: MO)
$69.58
Overall Grade6.5 / 10
Altria Group Inc., founded in 1985 and headquartered in Richmond, Virginia, United States, is one of the world’s largest producers and marketers of tobacco products. The company operates mainly in the tobacco industry while also engaging in diversified consumer product investments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E13.8
P/B-34.3
P/S5.4
P/FCF12.8
FCF Yield+7.8%
Growth & Outlook
Rev Growth (YoY)+1.2%
EPS Growth (YoY)+16.0%
Revenue 5yr-0.7%
EPS 5yr+29.0%
FCF 5yr+1.5%
Fundamentals
Market Cap$110.2B
Dividend Yield6.1%
Operating Margin+54.3%
ROE-243.6%
Interest Coverage10.3x
Competitive Edge
- Marlboro commands 45%+ retail share in a consolidated U.S. cigarette market with no meaningful new entrants possible due to FDA's pre-market tobacco application (PMTA) requirements. Regulatory barriers function as a permanent moat for incumbents.
- Altria's distribution network covering 200,000+ U.S. retail points gives on! and any future smoke-free products an unmatched go-to-market advantage. No nicotine pouch competitor, including Swedish Match (now PMI), can replicate this overnight.
- The Master Settlement Agreement creates a structural cost advantage for Altria over smaller competitors. Non-participating manufacturers face escrow requirements that effectively price them out of sustained competition at scale.
- Cigarette demand, while declining, is among the most recession-resistant consumer categories. Volume declines are predictable and gradual, allowing management to plan pricing actions years in advance with high confidence.
By the Numbers
- FCF margin of 42.3% with FCF-to-net-income conversion of 1.07x signals high earnings quality. Capex-to-OCF is just 3%, meaning nearly all operating cash flow drops to free cash flow. This is a business that barely needs reinvestment to sustain itself.
- PEG ratio of 0.68 against a forward P/E of 12.76x implies the market is underpricing the ~5% EPS growth trajectory. Trailing P/E of 15.5x compressing to 12.8x forward suggests consensus expects meaningful earnings acceleration from the $4.12 trailing base to $5.67.
- Smokeable products operating income grew 1.5% YoY to $10.98B despite a 3.4% revenue decline, implying roughly 260bps of margin expansion. Pricing power is more than offsetting volume declines, a pattern sustained across all four years of data.
- Total shareholder yield of 5.65% (6.3% dividend + 0.77% buyback + 1.36% debt paydown) is among the highest in Consumer Staples. The debt paydown component is often overlooked but reduces refinancing risk on the $24.6B debt stack.
- on! nicotine pouch shipments grew from 48.4M cans in FY2021 to 177.8M in FY2025, a 4-year CAGR of ~38%. Oral tobacco segment operating income surged 26.2% YoY to $1.83B, with margins expanding as the product scales past early investment phase.
Risk Factors
- Marlboro shipment volumes declined 12.2% YoY in FY2025, accelerating from the 9% decline in FY2024. Total cigarette volumes have fallen from 93.8B sticks in FY2021 to 61.8B, a 34% cumulative decline in four years. The pricing offset has a mathematical ceiling.
- Negative book value (-$1.91/share) and negative tangible book value (-$12.43/share) mean the $123B market cap sits on a balance sheet with no equity cushion. Debt-to-capital at 96% leaves zero margin for error if cash flows deteriorate unexpectedly.
- Other Operating Income (corporate/unallocated) exploded to -$2.53B in FY2025 from -$414M in FY2024, a $2.1B swing. This likely includes NJOY-related impairments or write-downs, given NJOY device shipments dropped to zero. That's a $2.1B capital allocation miss.
- Discount cigarette shipments surged 41.3% YoY in FY2025 after declining 30% in FY2024. This reversal signals consumer downtrading within Altria's own portfolio, which pressures revenue per stick and could erode Marlboro's premium positioning over time.
- on! shipment growth decelerated sharply from 40.2% in FY2024 to 10.9% in FY2025, and Q4 showed a 19% QoQ decline. If the oral tobacco growth engine is plateauing at ~180M cans, the narrative of next-generation product replacement weakens considerably.
Comcast Corporation (NASDAQ: CMCSA)
$24.87
Overall Grade6.5 / 10
Comcast Corporation, founded in 1963, is a diversified telecommunications conglomerate operating primarily in the United States. The company delivers a wide range of cable, broadband, and media services across multiple business segments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E5.7
P/B1.2
P/S0.8
P/FCF5.0
FCF Yield+19.8%
Growth & Outlook
Rev Growth (YoY)+1.3%
EPS Growth (YoY)-5.8%
Revenue 5yr+1.5%
EPS 5yr+10.8%
FCF 5yr+3.4%
Fundamentals
Market Cap$102.7B
Dividend Yield5.3%
Operating Margin+15.3%
ROE+19.8%
Interest Coverage4.3x
Competitive Edge
- Xfinity's broadband network creates a last-mile infrastructure moat with switching costs. Despite FWA competition from T-Mobile and Verizon, Comcast's DOCSIS 4.0 upgrade path offers multi-gig speeds without fiber-to-the-home capex, preserving capital efficiency.
- Xfinity Mobile's wireless line growth of 18.9% YoY (9.3M lines) is the fastest-growing segment and creates a bundling flywheel. Each wireless add deepens the customer relationship and raises switching costs, partially offsetting broadband churn.
- Universal's Epic Universe theme park opening in 2025 is a step-function capacity expansion. Theme Parks revenue already grew 14.1% in FY2025 to $9.8B, and Epic Universe should drive multi-year attendance and per-cap spending growth in the highest-margin segment.
- Peacock reaching 44M paid subscribers (up 22% YoY) gives Comcast a direct-to-consumer asset that retains content value in-house. Unlike pure-play streamers, Peacock losses are subsidized by the broader NBCUniversal content ecosystem and cable distribution.
By the Numbers
- FCF yield of 23% with FCF-to-net-income conversion at 1.11x signals high earnings quality. The $22.7B in unlevered FCF dwarfs the $1.3B in SBC (just 1% of revenue), meaning reported earnings are real cash, not inflated by non-cash adjustments.
- Total shareholder yield of 15.1% (4.7% dividend + 7.2% buyback + 3.2% debt paydown) is extraordinary. The $6.4B in buybacks is actively shrinking the float, with shares declining 1.1% YoY, not just offsetting dilution.
- Trailing P/E of 4.9x and EV/EBITDA of 4.8x price this as a distressed asset, yet FCF margin of 16.3% and ROE near 20% indicate a profitable, cash-generative business. The disconnect between valuation and fundamentals is stark.
- Connectivity & Platforms EBITDA margin expanded from 37% in FY2021 to 40% in FY2024 even as total segment revenue was flat, showing disciplined cost extraction from a shrinking subscriber base. ARPU grew to $131.77/month, up from $129.41 in FY2022.
- FCF payout ratio of 24% versus earnings payout ratio of 26% confirms the dividend is backed by cash, not accounting earnings. With $5.56 FCF per share against $1.34 in dividends, there is over 4x coverage.
Risk Factors
- Domestic broadband net additions deteriorated from +1.26M in FY2021 to -654K in FY2025, a structural reversal. Total connectivity customer relationships lost 967K in FY2025, accelerating from -527K the prior year. This is not cyclical, it is secular erosion.
- Tangible book value per share is negative $12.24, meaning 51% of total assets ($141B) are intangibles and goodwill, largely from the Sky and NBCUniversal acquisitions. At P/B of 1.0x, you are paying book value for a balance sheet dominated by acquisition premiums.
- Revenue growth has flatlined: 1.3% YoY, 1.0% 3Y CAGR, 1.5% 5Y CAGR. Analyst estimates project revenue declining slightly to $120.2B in Y2 before recovering. With EPS also falling from $5.39 trailing to an estimated $3.53 in Y1, the earnings trajectory is negative near-term.
- Net debt of $85.1B against $37.4B in consolidated EBITDA (2.25x leverage) looks manageable, but the current ratio of 0.87 and quick ratio of 0.71 indicate short-term liquidity is tight. Refinancing $94.6B in total debt in a higher-rate environment compresses future FCF.
- Content & Experiences EBITDA fell 4% YoY in FY2025 and collapsed 67% QoQ in the most recent quarter. Media revenue dropped 3.8% annually despite Peacock growing to 44M paid subs, suggesting linear TV ad revenue declines are overwhelming streaming gains.
Verizon Communications Inc (NYSE: VZ)
$47.81
Overall Grade6.2 / 10
Verizon Communications Inc. is a global leader in delivering communications, technology, information, and entertainment products and services...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E12.2
P/B2.0
P/S1.5
P/FCF10.3
FCF Yield+9.7%
Growth & Outlook
Rev Growth (YoY)+0.7%
EPS Growth (YoY)+1.0%
Revenue 5yr+0.8%
EPS 5yr-5.1%
FCF 5yr-2.1%
Fundamentals
Market Cap$209.6B
Dividend Yield5.9%
Operating Margin+21.2%
ROE+16.9%
Interest Coverage4.2x
Competitive Edge
- Verizon's 5G C-band spectrum holdings create a durable capacity advantage over T-Mobile in dense urban markets. Spectrum is a finite, government-allocated resource with no substitute, making it the closest thing to a permanent moat in wireless.
- Fixed wireless access is cannibalizing cable broadband (Comcast, Charter) without requiring last-mile fiber buildout. Verizon is reusing existing tower infrastructure, turning a wireless asset into a broadband competitor at fraction of traditional deployment cost.
- The 6.7% dividend yield at current prices creates a natural floor for institutional and income-oriented holders. In a declining rate environment, this yield becomes increasingly attractive relative to fixed income alternatives, compressing downside risk.
- Fios fiber footprint in the Northeast corridor serves the densest, highest-ARPU markets in the U.S. Unlike cable competitors facing fiber overbuild risk, Verizon already owns the fiber, giving it structural cost advantages in its served territories.
- Wireless industry consolidation to three national carriers (Verizon, T-Mobile, AT&T) creates rational pricing discipline. DISH/EchoStar remains a weak fourth player, reducing the risk of a price war that would compress industry margins.
By the Numbers
- PEG of 0.49 against a forward P/E of 10.3x signals the market is underpricing Verizon's estimated EPS growth from $4.06 trailing to $4.91 in Y1 and $5.21 in Y2, a 21% and 28% cumulative increase that the valuation barely reflects.
- FCF yield of 9.6% with FCF-to-net-income conversion of 1.14x indicates earnings quality is strong. Cash generation exceeds reported profits, meaning the income statement actually understates economic earnings power.
- Consumer broadband connections grew 8.4% YoY to 10.86M, the fastest-growing KPI in the portfolio. This fixed wireless access ramp is layering a second revenue stream onto existing wireless infrastructure with minimal incremental capex.
- Consumer ARPA grew from $122.30 in FY2021 to $138.25 in FY2024, a 13% cumulative increase, while postpaid connections grew only 3.9% over the same period. Monetization per account is doing the heavy lifting, not subscriber volume.
- Capex-to-depreciation of 0.93x means Verizon is spending less on capex than it depreciates, suggesting the C-band buildout cycle is peaking. As capex normalizes lower, FCF should expand even on flat revenue.
Risk Factors
- Net debt of $162.6B at 2.93x EBITDA with interest coverage of only 7.1x leaves thin margin for error. At current OCF-to-debt of 23.4%, it would take over 4 years of entire operating cash flow to retire total debt, and that ignores dividends and capex.
- EPS has declined at a -7.1% 3-year CAGR and -1.1% over 5 years despite stable revenue, meaning margin compression and rising interest expense are eating into profitability. The Growth grade of 3.6/10 confirms this structural weakness.
- Consumer wireless postpaid net adds fell 56.8% YoY to 581K in FY2025 while Q3 showed a sharp QoQ decline before a Q4 surge. The volatility suggests promotional dependency rather than organic demand, and the annual trend is clearly decelerating from the 2.04M peak in FY2023.
- Business segment revenue has declined for four consecutive years, from $31.07B in FY2022 to $29.07B in FY2025, a cumulative 6.4% erosion. Business operating income fell 26% from FY2021 to FY2024 before a partial bounce. This segment is structurally shrinking.
- Tangible book value per share is negative $20.30, driven by intangibles comprising 47% of total assets. The $181.6B debt load sits on top of a balance sheet where nearly half the assets are spectrum licenses and goodwill, assets that cannot be easily liquidated.
PepsiCo Inc. (NASDAQ: PEP)
$144.19
Overall Grade5.8 / 10
PepsiCo Inc., founded in 1898 and restructured in 1965, is a global multinational operating in the food, snack, and beverage industry. It serves consumers in over 200 countries with a wide-ranging portfolio of products...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E23.6
P/B9.6
P/S2.2
P/FCF23.2
FCF Yield+4.3%
Growth & Outlook
Rev Growth (YoY)+1.6%
EPS Growth (YoY)+6.2%
Revenue 5yr+3.7%
EPS 5yr+3.0%
FCF 5yr+1.0%
Fundamentals
Market Cap$205.3B
Dividend Yield4.1%
Operating Margin+12.7%
ROE+41.8%
Interest Coverage10.5x
Competitive Edge
- PepsiCo's dual food-and-beverage model creates unique distribution synergies. Frito-Lay's direct-store-delivery network covers over 300,000 U.S. retail locations, giving snack brands shelf-space control that Mondelez, Kellanova, and pure-play competitors cannot replicate at comparable cost.
- The FY2025 segment reorganization (merging Frito-Lay and Quaker into PFNA, creating IB Franchise) signals management is optimizing for margin extraction and accountability. Consolidating the struggling Quaker business under Frito-Lay's stronger management team could accelerate the recall recovery.
- PepsiCo's franchise-based international beverage model (IB Franchise segment grew operating profit 21% YoY) is asset-light and high-margin. This structure mirrors Coca-Cola's bottler refranchising playbook, reducing capital intensity while capturing concentrate economics.
- Category positioning in salty snacks is structurally advantaged. Frito-Lay holds ~60% U.S. market share in salty snacks, a category with high impulse-purchase frequency, low private-label penetration, and minimal GLP-1 drug exposure compared to sugary beverages or confections.
- Emerging market food platforms in Latin America and Asia Pacific provide long-duration growth runways. LatAm Foods generates 19% operating margins on $10.5B revenue, and the category benefits from rising snacking occasions as developing-market consumers shift toward packaged convenience foods.
By the Numbers
- PEG ratio of 0.41 is striking given forward P/E of 18.1x, implying consensus expects ~44% EPS growth from trailing $6.00 to $8.63 in Y1. That gap between trailing and forward earnings suggests FY2025 had significant one-time charges depressing the $6 trailing EPS figure.
- ROIC of 13.5% comfortably exceeds PepsiCo's weighted average cost of capital (likely 7-8%), confirming the business still creates real economic value despite 2.4x debt/equity. The 42.8% ROE is amplified by leverage but the underlying asset productivity at 9% ROA is solid for consumer staples.
- Negative cash conversion cycle of -124 days is a massive working capital advantage. PepsiCo collects from customers and turns inventory far faster than it pays suppliers (DPO of 213 days), effectively using vendor financing to fund operations and reduce capital needs.
- SBC/revenue at just 0.3% is negligible, meaning reported margins closely approximate true cash economics. Unlike tech peers, virtually no hidden dilution cost is embedded in the P&L, and buybacks (0.43% yield) are genuinely returning capital rather than offsetting option grants.
- FCF-to-net-income conversion of 0.92x is healthy, and OCF-to-net-income of 1.46x shows strong cash generation above reported earnings. Capex/depreciation at 1.06x means the company is roughly maintaining its asset base without overinvesting, keeping free cash flow clean.
Risk Factors
- FCF payout ratio at 99.8% leaves essentially zero margin of safety for the dividend. With $5.58 FCF per share and $5.58 dividend per share, any modest decline in free cash flow forces either dividend cuts or incremental borrowing to maintain the payout.
- Total organic volume declined 2% company-wide in FY2025 while net pricing grew 4%, meaning 100% of organic revenue growth came from price increases. This pricing-over-volume dynamic has persisted for three years and raises demand elasticity risk as consumer pushback builds.
- PBNA segment operating profit collapsed 52.7% YoY to $1.09B despite revenue growing 1.5%. Operating margin cratered from ~8.3% to ~3.9%, suggesting either a major restructuring charge, competitive pricing pressure, or cost inflation that management couldn't offset in the beverage business.
- Tangible book value per share is negative at -$9.89, with intangibles/goodwill comprising 31.6% of total assets. The 10.3x P/B multiple rests entirely on brand value and earnings power. Any impairment to the $17.6B goodwill balance would directly hit equity.
- Current ratio of 0.85 and quick ratio of 0.64 indicate short-term liabilities exceed liquid assets. While common for consumer staples with strong cash flows, combined with net debt/EBITDA of 2.5x and $49B total debt, refinancing risk is non-trivial if credit markets tighten.
Chevron Corporation (NYSE: CVX)
$182.46
Overall Grade5.6 / 10
Chevron Corporation is a global integrated energy company operating across the oil, natural gas, and petrochemical sectors. Originally founded in 1879 as the Pacific Coast Oil Co., it has grown to become one of the world’s largest energy firms with a significant international presence...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E35.9
P/B2.2
P/S2.2
P/FCF29.9
FCF Yield+3.3%
Growth & Outlook
Rev Growth (YoY)+0.8%
EPS Growth (YoY)-13.0%
Revenue 5yr+3.6%
EPS 5yr-6.7%
FCF 5yr-13.7%
Fundamentals
Market Cap$412.1B
Dividend Yield3.9%
Operating Margin+8.2%
ROE+5.9%
Interest Coverage11.3x
Competitive Edge
- The Hess acquisition added Guyana's Stabroek block, one of the highest-return deepwater assets globally with breakevens below $35/bbl. This gives CVX a decade-plus growth runway in a basin where ExxonMobil is the only comparable operator.
- CVX's integrated model provides a natural hedge: when crude prices fall, refining margins often expand as input costs drop. FY2025's downstream recovery while upstream earnings declined demonstrates this countercyclical offset in real time.
- Permian Basin position as the second-largest acreage holder behind ExxonMobil provides low-decline, high-return inventory that generates cash even at $50 WTI. Short-cycle shale investment can flex quickly with commodity prices.
- Chevron's LNG portfolio, including Gorgon, Wheatstone, and equity in global projects, positions it for structural demand growth as Asian and European buyers seek long-term gas supply security post-Russia sanctions.
- Minimal goodwill at 1.4% of assets means the balance sheet carries almost no acquisition impairment risk despite the Hess deal, likely because Hess was structured to avoid massive goodwill creation through reserve-based purchase accounting.
By the Numbers
- Total upstream production surged 11.5% YoY to 3,723 MBOED in FY2025, with U.S. production up 16.2% to 1,858 MBOED. This volume growth is clearly Hess-acquisition driven and gives CVX a structurally higher production base even if commodity prices weaken.
- FCF-to-net-income ratio of 1.33x indicates earnings quality is solid, with cash generation exceeding reported profits. OCF-to-net-income at 2.72x confirms strong non-cash charge coverage and real cash backing behind reported earnings.
- Interest coverage at 30x with net debt/EBITDA under 1.0x gives CVX significant financial flexibility during a commodity downturn. Even if EBITDA halved, coverage would remain comfortable, a critical advantage in a cyclical business.
- Downstream segment earnings rebounded 75% YoY to $3.0B in FY2025 after collapsing 72% in FY2024, while downstream capex was cut 45% YoY. This margin recovery on lower investment suggests refining crack spreads are normalizing, not that CVX is spending its way to growth.
- Buyback yield of 5.0% combined with 4.5% dividend yield delivers nearly 9.5% total cash return. With capex/OCF at 51%, roughly half of operating cash flow is available for shareholder returns even at current spending levels.
Risk Factors
- Payout ratio at 103.7% of earnings means CVX is paying more in dividends than it earns. While FCF payout at 77% is more sustainable, any further commodity price decline compresses FCF and puts the dividend commitment under real pressure.
- Upstream U.S. earnings fell 23.5% YoY and upstream international earnings dropped 36.3% in FY2025, despite production volumes rising 16%. This means realized prices and margins per barrel are deteriorating sharply, masking the volume growth story.
- EPS has declined at a negative 28.7% 3-year CAGR while FCF contracted at a negative 32.1% 3-year CAGR. The trailing P/E of 30x on trough-ish earnings looks optically cheap only if you assume a strong commodity recovery that consensus estimates require.
- Capex-to-depreciation at 0.86x means CVX is spending less than its depreciation charge, essentially underinvesting relative to asset base depletion. This flatters near-term FCF but raises questions about reserve replacement and long-term production sustainability.
- The 'All Other' segment losses widened 33% YoY to negative $3.5B in FY2025. This corporate drag, likely including new energy ventures and overhead, is growing faster than any profit center and quietly eroding consolidated returns.
Medtronic plc (NYSE: MDT)
$73.81
Overall Grade5.2 / 10
Medtronic plc is a global medical technology company founded in 1949 that develops and manufactures innovative therapies and devices for the health care sector. It operates across multiple therapeutic areas with a core focus on improving patient outcomes and quality of life...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E28.1
P/B2.6
P/S3.6
P/FCF23.9
FCF Yield+4.2%
Growth & Outlook
Rev Growth (YoY)+2.1%
EPS Growth (YoY)-3.2%
Revenue 5yr+2.2%
EPS 5yr+0.7%
FCF 5yr-1.7%
Fundamentals
Market Cap$129.3B
Dividend Yield3.9%
Operating Margin+17.0%
ROE+9.5%
Interest Coverage8.5x
Competitive Edge
- MDT's installed base of implantable devices (pacemakers, spinal stimulators, insulin pumps) creates recurring revenue through replacements, consumables, and software upgrades. Switching costs are enormous because physicians train on specific platforms and hospitals integrate with MDT's data systems.
- The 780G insulin pump with Guardian 4 sensor has recaptured share from Insulet and Dexcom/Tandem, driving the diabetes turnaround. FDA clearance in the U.S. and international expansion give MDT a competitive product for the first time in years in this high-growth category.
- Regulatory moats in medtech are real: FDA 510(k) and PMA pathways create 2-5 year barriers for competitors on each product. MDT's breadth across cardiac, neuro, spine, and surgical means it can bundle procurement contracts that smaller competitors cannot match.
- Hugo robotic surgical system positions MDT against Intuitive Surgical's da Vinci monopoly. While still early, MDT's existing hospital relationships and service infrastructure give it a distribution advantage that pure-play robotics entrants lack.
- Geographic diversification is genuine: 51% U.S., 30% developed international, 18% emerging markets. Emerging markets grew 6.5% in FY2025 and represent the highest structural growth runway as procedure volumes expand in China, India, and Southeast Asia.
By the Numbers
- PEG of 0.27 is striking: forward PE of 15.66x against consensus EPS growth from $5.65 to $7.78 over five years implies ~7.8% CAGR, yet the market prices MDT like a no-growth utility. The gap between trailing PE (24.3x) and forward PE (15.66x) signals a 55% earnings step-up already baked into estimates.
- Diabetes segment is the hidden accelerator: 11.5% organic growth in FY2025 with operating profit surging 24.6% YoY to $491M. Margins are inflecting as the 780G system gains share, and this segment's profit contribution is still only ~4% of total, meaning upside is asymmetric.
- FCF-to-net-income conversion of 1.17x confirms high earnings quality. OCF-to-net-income at 1.57x with capex/OCF at just 25.7% shows the business generates real cash well above reported earnings, a rarity for a company with $28B in debt.
- Cardiovascular organic growth accelerated from 4% to 5% to 6.3% over FY2023-FY2025, the strongest three-year trend in the portfolio. With the segment now 37% of revenue and margins expanding (operating profit +7.3% on +5.5% revenue), this is genuine operating leverage.
- Current ratio of 2.54 and cash ratio of 0.88 are unusually strong for a $129B medtech company carrying $28B debt. With $8.3B cash and $7.3B OCF, MDT could retire all net debt in under 2.7 years from free cash flow alone.
Risk Factors
- Medical Surgical organic growth collapsed from 4.7% in FY2024 to 0.8% in FY2025, yet this segment still represents 25% of revenue. Operating profit fell 4% YoY despite flat revenue, signaling margin pressure. Surgical & Endoscopy revenue was essentially flat at -0.2%.
- Goodwill at 45.8% of total assets and intangibles at 57.1% leave tangible book value per share at negative $2.52. The $2.29 P/B ratio is meaningless when the tangible equity is wiped out, meaning shareholders are entirely dependent on earnings power with zero asset floor.
- Payout ratio of 78.6% on earnings and 67.4% on FCF leaves minimal cushion. With only ~$1.7B of FCF remaining after dividends ($3.6B) and buybacks ($0.4B), there is almost no financial flexibility for bolt-on acquisitions without incremental debt.
- Revenue per share grew from ~$25.5 (implied 5Y ago) to $27.55, a 1.6% CAGR, while reported revenue grew 2.2% CAGR over 5 years. Share dilution consumed roughly 27% of top-line growth, despite buyback yield of 0.31%. SBC is modest at 1.3% of revenue but buybacks barely offset it.
- Cash conversion cycle of 173 days is extremely long, driven by 182 days inventory on hand. Inventory turnover of 2.0x suggests either product complexity or demand softness. DIO this elevated in medtech warrants monitoring for obsolescence risk on older device platforms.
Duke Energy Corporation (NYSE: DUK)
$122.73
Overall Grade4.4 / 10
Duke Energy Corporation, founded in 1904, is one of the largest electric power holding companies in the United States, primarily serving the Midwest and Southeast with regulated electricity and natural gas services. The company generates revenue through its regulated utility operations including electricity generation, transmission, and distribution along with natural gas distribution...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E20.1
P/B1.9
P/S3.1
P/FCF-30.9
FCF Yield-3.2%
Growth & Outlook
Rev Growth (YoY)+2.9%
EPS Growth (YoY)+3.5%
Revenue 5yr+6.1%
EPS 5yr+6.9%
FCF 5yr-
Fundamentals
Market Cap$101.9B
Dividend Yield3.5%
Operating Margin+27.2%
ROE+9.6%
Interest Coverage2.4x
Competitive Edge
- Duke operates in some of the fastest-growing load territories in the U.S. (Carolinas, Florida), where data center demand and population migration create organic rate base growth without needing acquisitions.
- Regulated utility model with ~100% regulated earnings provides visibility that few sectors can match. Rate cases in NC, SC, FL, IN, and OH create a staggered, predictable earnings cadence with limited commodity exposure.
- Grid modernization and clean energy transition mandates (NC HB 951, Carbon Plan) essentially guarantee regulatory approval for multi-decade capex programs, locking in rate base growth through the 2030s.
- The 2022 exit from Commercial Renewables (segment went to zero) removed merchant power risk and simplified the story to pure regulated returns, reducing earnings volatility and improving regulatory relationships.
- Duke's monopoly service territories face no competitive threat from retail deregulation. Switching costs are infinite for captive ratepayers, making the revenue base as durable as any in corporate America.
By the Numbers
- Electric Utilities segment income grew 11.9% YoY in FY2025 on only 4.5% revenue growth, showing strong operating leverage as rate base investments convert to earnings at an accelerating pace.
- EPS growth is running well ahead of revenue: 3Y EPS CAGR of 25.8% vs 3.9% revenue CAGR, indicating successful rate case outcomes and cost discipline are amplifying modest top-line gains into meaningful earnings expansion.
- OCF-to-net-income ratio of 2.43x is excellent for a regulated utility, confirming earnings quality is high. Depreciation and deferred tax shields generate substantial cash above reported net income.
- EBITDA growth accelerated to 13.8% YoY, up from the 5Y CAGR of 10.2%, suggesting the massive capex program ($12.6B in electric alone in FY2025) is now hitting the rate base and flowing through to allowed returns.
- Consensus estimates project steady 6-7% EPS growth through FY2029 ($6.70 to $8.66), consistent with management's guided range, and 13 analysts covering suggests strong institutional attention and estimate reliability.
Risk Factors
- FCF is deeply negative at -$1.7B (FCF margin of -5.3%), and capex-to-OCF of 1.14x means the company spends more on capex than it generates in operating cash. Every dollar of dividends and growth requires external financing.
- Net debt/EBITDA of 5.1x is at the upper end of what rating agencies tolerate for investment-grade utilities. With $90.9B in total debt and only $245M in cash, refinancing risk is real if credit spreads widen.
- Shareholder yield is deeply negative at -6.2%, driven by continuous debt issuance (debt paydown yield of -6.3%) and slight share dilution. Investors are funding the capex cycle through balance sheet expansion, not organic cash flow.
- Current ratio of 0.55 and quick ratio of 0.21 are thin even by utility standards. Short-term liquidity depends entirely on revolving credit facilities and commercial paper access, which could tighten in a credit stress scenario.
- The FCF payout ratio of -194.8% confirms the 3.6% dividend yield is entirely funded by debt issuance, not free cash flow. The 67% earnings payout ratio masks that cash coverage is nonexistent.
This is a weird list, and I mean that as a compliment. You’ve got a semiconductor giant sitting next to a school bus manufacturer, a gold miner next to an offshore vessel company. That’s not sloppy curation. That’s what happens when you screen for dividend quality without caring about sector labels. The U.S. market lets you do that in a way the TSX simply can’t.
What I’d push back on is the instinct to treat all ten of these the same way. Some are mature cash flow machines where the dividend is the primary return driver. Others are earlier in their payout journey, where the real money comes from earnings growth pulling the stock price higher while the dividend tags along. Those two types of holdings serve completely different roles in a portfolio, and confusing them leads to bad expectations.
If a name here yields 1% but is growing that payout at double digits, don’t compare it to your Canadian bank stock yielding 5%. Compare it to what that 1% becomes in five years. That reframe changes everything.
